GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Vir Biotechnology

The FDA restricts the use of sotrovimab, Glaxo (GSK)/Vir's (VIR) COVID therapy, in several states and territories based on the latest data that does not support the therapy's effectiveness against a dominating Omicron subvariant.

FDA Revises EUA of Glaxo (GSK) & Vir's (VIR) COVID Therapy

The FDA said that the currently authorized 500mg dose of GlaxoSmithKline Plc (NYSE: GSK) and Vir Biotechnology Inc's (NASDAQ: VIR) COVID-19 antibody therapy is unlikely to be effective against the omicron BA.2 variant. The agency updated its website to exclude.

FDA Says Current Dose Of GSK-Vir's COVID-19 Therapy Unlikely To Work Against Omicron Subvariant

BiondVax Pharmaceuticals

JERUSALEM, March 28, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today published its fourth quarter and full year financial results for the year ended December 31, 2021 and provided a business update.

BiondVax Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere, today announced a strategic R&D collaboration with GlaxoSmithKline (GSK). The collaboration will provide GSK with access to LifeMine's genomically enabled drug discovery platform to identify novel small molecule leads directed to up to three human targets provided by GSK addressing multiple disease area

LifeMine Therapeutics and GSK Enter Drug Discovery and Development Alliance

Do investors want to take a chance on GlaxoSmithKline PLC ( GSK , Financial) reporting positive results mid-year from the key trial of its respiratory syncytial virus vaccine?

GlaxoSmithKline Needs Positive Outcome of RSV Vaccine Clinical Trial

GlaxoSmithKline PLC (LSE:GSK) workers are to be balloted for a potential strike over a pay dispute, according to union Unite. After being offered a pay increase of 2.75%, with an offer of 4% potentially available "but with considerable strings attached", the union said its 1,000 or more workers who work for the FTSE 100 pharmaceutical company said the offers have both been rejected.

GlaxoSmithKline workers to vote on strike over 2.75% pay offer

This week's Filing Season Finds report highlights some of the most interesting footnote disclosures in the 176 10-Ks and 10-Qs the Robo-Analyst analyzed last week.

GlaxoSmithKline's Understated Profits & More From The Real Earnings Season

Britain's GlaxoSmithKline will move to prioritising supply of essential medicines in Russia after sanctions were imposed against Moscow for its invasion of Ukraine, joining other drugmakers with similar responses to the crisis.

GSK to supply essential medicines to Russia, halts clinical trials

GlaxoSmithKline PLC (LON:GSK) is definitely a fundamentally endowed company. That said, investors cannot buy-in at any price.

GlaxoSmithKline is an attractive stock. How do you know when to buy?

AbbVie

Bristol-Myers

Johnson & Johnson

Merck

Novartis

Pfizer

As Viatris and other generic drug makers plunge, what should you buy instead? Consider these seven well-known drug stocks, all of which are good value in what's still a pricey market.

7 Drug Stocks to Consider After the Viatris Plunge

GlaxoSmithKline PLC (GSK) Presents at UBS Global Consumer and Retail Conference 2022 (Transcript)

GlaxoSmithKline plc (GSK) Management Presents at 42nd Annual Cowen Health Care Conference (Transcript)

Vir Bio has a COVID blockbuster in Xevudy, and the stock is super-cheap right now.

Here's Why This Under-the-Radar Biotech Is at the Top of My Buy List

Walgreens

CVS Health

Kroger

Rite Aid

President Joe Biden announced during his State of the Union address on Tuesday that individuals who test positive for Covid-19 at a pharmacy will soon be able to get free antiviral treatments immediately after. The cost will be funded by the federal government, which could result in a huge boost to the revenue of companies in the pharmaceutical, pharmacy and diagnostic industries over the coming year.

Health Care Stocks to Watch as Test to Treat Plan Looks to Prevent Lockdowns

Moderna

Thermo Fisher Scientific

President Joe Biden announced during his State of the Union address on Tuesday that individuals who test positive for Covid-19 at a pharmacy will soon be able to get free antiviral treatments immediately after. The cost will be funded by the federal government, which could result in a huge boost to the revenue of companies in the pharmaceutical, pharmacy, and diagnostic industries over the coming year.

Test to Treat Plan can Boost these Stocks

Innovative Industrial Properties

They won't make you rich, but they'll yield some steady income.

Need an Extra $1,000 Per Year? Buy and Hold These 2 Stocks

GlaxoSmithKline PLC (LSE:GSK) hit a major milestone after its drug for treating chronic kidney disease gained marketing permission from the European Medicines Agency. The group said in its ASCEND Phase III clinical trial programme for daprodustat , which consisted of five trials, all met their co-primary efficacy and safety endpoints.

GlaxoSmithKline gains European marketing approval for kidney disease drug daprodustat

GlaxoSmithKline Plc (NYSE: GSK) has halted enrollment and vaccination in three trials of its experimental vaccine against the respiratory syncytial virus (RSV) in pregnant women. Last week, GSK paused a late-stage trial, dubbed "GRACE," as well as two other studies.

GSK Stops Additional Three Respiratory Virus Vaccine Trials In Pregnant Women

Haleon, which makes brands including Sensodyne toothpaste, expects annual sales growth of between 4% and 6% in 2022.

GlaxoSmithKline to Spin Off Haleon Consumer Business in July

Gilead Sciences

These stocks offer attractive dividends and more.

3 Pharma Stocks That Retired Investors Should Love

AstraZeneca

The FDA authorized an increased dose in the case of AstraZeneca Plc's (NASDAQ: AZN) pre-exposure prophylaxis drug Evusheld (tixagevimab and cilgavimab). "Based on the most recent information and data available, Evusheld may be less active against certain Omicron.

AstraZeneca, GSK's COVID-19 Therapies Lose Efficacy Against Omicron's Subvariants

GlaxoSmithKline has received regulatory approval for its first Covid vaccine almost 14 months after UK rival AstraZeneca began dosing patients. Canada has given approval for Covifenz, an adjuvanted plant-based COVID-19 vaccine developed by the UK pharma giant in collaboration with Quebec-based Medicago (TSX:MDG).

GlaxoSmithKline gets first Covid-19 vaccine approved

QUEBEC CITY & LONDON--(BUSINESS WIRE)--Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) today announced that Health Canada has granted approval for COVIFENZ®, COVID-19 vaccine, (plant-based virus-like particles [VLP], recombinant, adjuvanted). This vaccine is indicated for active immunization to prevent coronavirus disease 2019 (COVID‑19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) in individuals 18 to 64 years of age. “The

Medicago and GSK Announce the Approval by Health Canada of COVIFENZ®, an Adjuvanted Plant-Based COVID-19 Vaccine

Sanofi

GlaxoSmithKline PLC (LSE:GSK) and Sanofi SA said they plan to submit data from their booster and Phase III trials as a basis for their regulatory applications for a COVID-19 vaccine. The companies are in talks with regulatory authorities, including the US Food & Drug Administration and the European Medicines Agency.

GlaxoSmithKline and Sanofi plan to submit data from COVID-19 booster and Phase III trials for approval

Sanofi SA SNY, -0.80% and GlaxoSmithKline PLC GSK, -0.81% said Wednesday that their jointly-developed coronavirus vaccine has shown positive results in final-stage clinical trials and that they intend to seek regulatory approval for the shot.

News for GlaxoSmithKline Stock (GSK)